Table 4 Hybrid liposome in cancer detection
Liposomes | Cancer | Detection agent and methods | Characteristics of hybrid liposomes | Explain | References |
|---|---|---|---|---|---|
Hybrid liposomes (HLs) are composed of vesicular and micellar molecules | Colorectal cancer (CRC) | HLs encapsulating a fluorescent probe (ICG) Fluorescence imaging | A combination of 90% DMPC and 10% polyoxyethylene (25% dodecyl ether) was sonicated to produce HLs. While DMPC LPs had a hydrodynamic diameter (dhy) of 200–300 nm, HLs had a dhy of less than 100 nm. The DMPC LPs fell apart. Retinal endothelial system evasion is possible for HLs smaller than 100 nm | After intravenous treatment, the accumulation of HLs encapsulating a fluorescent probe (ICG) was shown in HCT116 cells in the in vivo CRC model, facilitating the identification and detection of HLs | [172] |
Cell membrane-camouflaged nanoliposome (Bio-Lipo-CB) | Triple-negative breast cancer (TNBC) | A fluorescence imaging test conducted in vivo revealed that Bio-Lipo-CB | The thin-layer evaporation technique was used to manufacture Bio-Lipo-CB. Ce6 had an EE of 60.0 in Bio-Lipo-CB, whereas BMS202 had an efficiency of 71.2%. Around 150 nm was the size of the Bio-Lipo-CB. Compared to Lipo-CB, which had a particle size of around 90 nm, this was 1.6 times bigger. Compared to Lipo-CB, whose ζ-potential is −24.06 mV, Bio-Lipo-CB has a much lower value of −3.47 mV | The in vivo anticancer experiment further proved the effectiveness of the Bio-Lipo-CB-SDT study against tumors and also showed that Bio-Lipo-CB-SDT produced ICD | [174] |
LP–exosome (EXO) hybrids | breast cancer (BC) | A unique and sensitive in situ detection technique for exosomal miR-1246 by combining the CRISPR/Cas13a system with the production of hybrids between cationic LPs and EXOs | As opposed to the spherical shape of EXOs and LPs, signs of LP-HE included bridging membranes and large vesicles. The size of the EXOs and LPs in the combination increased to around 350 nm, which is larger than either component alone and suggests the formation of hybrids | In addition to identifying serum exosomal miR-1246, this method may be used to distinguish between individuals with BC who are in the early or late stages of the disease. In the future, exosomal miRNA analysis may use this methodology | [176] |